Literature DB >> 31578051

Exercise programmes for ankylosing spondylitis.

Jean-Philippe Regnaux1, Thomas Davergne, Clémence Palazzo, Alexandra Roren, François Rannou, Isabelle Boutron, Marie-Martine Lefevre-Colau.   

Abstract

BACKGROUND: Exercise programmes are often recommended for managing ankylosing spondylitis (AS), to reduce pain and improve or maintain functional capacity.
OBJECTIVES: To assess the benefits and harms of exercise programmes for people with AS. SEARCH
METHODS: We searched CENTRAL, the Cochrane Library, MEDLINE Ovid, EMBASE Ovid, CINAHL EBSCO, PEDro, Scopus, and two trials registers to December 2018. We searched reference lists of identified systematic reviews and included studies, handsearched recent relevant conference proceedings, and contacted experts in the field. SELECTION CRITERIA: We included reports of randomised controlled trials (RCT) of adults with AS that compared exercise therapy programmes with an inactive control (no intervention, waiting list) or usual care. DATA COLLECTION AND ANALYSIS: We used standard Cochrane methodology. MAIN
RESULTS: We included 14 RCTs with 1579 participants with AS. Most participants were male (70%), the median age was 45 years (range 39 to 47), and the mean symptom duration was nine years. The most frequently used exercises were those designed to help improve strength, flexibility, stretching, and breathing. Most exercise programmes were delivered along with drug therapy or a biological agent. We judged most of the studies at unclear or high risk of bias for several domains. All 14 studies provided data obtained immediately upon completion of the exercise programme. The median exercise programme duration was 12 weeks (interquartile range (IQR) 8 to 16). Three studies (146 participants) provided data for medium-term follow-up (< 24 weeks after completion of the exercise programmes), and one (63 participants) for long-term follow-up (> 24 weeks after completion of the exercise programmes). Nine studies compared exercise programmes to no intervention; five studies compared them to usual care (including physiotherapy, medication, or self-management).Exercise programmes versus no interventionAll data were obtained immediately upon completion of the exercise programme.For physical function, measured by a self-reporting questionnaire (the Bath Ankylosing Spondylitis Functional Index (BASFI) scale, 0 to 10; lower is better), moderate-quality evidence showed a no important clinically meaningful improvement with exercise programmes (mean difference (MD) -1.3, 95% confidence interval (CI) -1.7 to -0.9; 7 studies, 312 participants; absolute reduction 13%, 95% CI 17% to 9%).For pain, measured on a visual analogue scale (VAS, 0 to 10, lower is better), low-quality evidence showed an important clinically meaningful reduction of pain with exercise (MD -2.1, 95% CI -3.6 to -0.6; 6 studies, 288 participants; absolute reduction 21%, 95% CI 36% to 6%).For patient global assessment of disease activity, measured by a self-reporting questionnaire (the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scale, 0 to 10, lower is better), moderate-quality evidence showed no important clinically meaningful reduction with exercise (MD -0.9, 95% CI -1.3 to -0.5; 6 studies, 262 participants; absolute reduction 9%, 95% CI 13% to 5%).For spinal mobility, measured by a self-reporting questionnaire (the Bath Ankylosing Spondylitis Metrology Index (BASMI) scale, 0 to 10, lower is better), very low-quality evidence showed an improvement with exercise (MD -0.7 95%, -1.3 to -0.1; 5 studies, 232 participants) with no important clinical meaningful benefit (absolute reduction 7%, 95% CI 13% to 1%).For fatigue, measured on a VAS (0 to 10, lower is better), very low-quality evidence showed a no important clinically meaningful reduction with exercise (MD -1.4, 95% CI -2.7 to -0.1; 2 studies, 72 participants; absolute reduction 14%, 95% CI 27% to 1%).Exercise programmes versus usual careAll data were obtained immediately upon completion of the exercise programme.For physical function, measured by the BASFI scale, moderate-quality evidence showed an improvement with exercise (MD -0.4, 95% CI -0.6 to -0.2; 5 studies, 1068 participants). There was no important clinical meaningful benefit (absolute reduction 4%, 95% CI 6% to 2%).For pain, measured on a VAS (0 to 10, lower is better), moderate-quality evidence showed a reduction of pain with exercise (MD -0.5, 95% CI -0.9 to -0.1; 2 studies, 911 participants; absolute reduction 5%, 95% CI 9% to 1%). No important clinical meaningful benefit was found.For patient global assessment of disease activity, measured by the BASDAI scale, low-quality evidence showed a reduction with exercise (MD -0.7, 95% CI -1.3 to -0.1; 5 studies, 1068 participants), but it was not clinically important (absolute reduction 7%, 95% CI 13% to 1%) with important clinical meaningful benefitFor spinal mobility, measured by the BASMI scale, very low-quality evidence found a no important clinically meaningful improvement with exercise (MD -1.2, 95% CI -2.8 to 0.5; 2 studies, 85 participants; absolute reduction 12%, 95% CI 5% less to 28% more). There was no important clinical meaningful benefit.None of the studies measured fatigue.Adverse effectsWe found very low-quality evidence of the effect of exercise versus either no intervention, or usual care. We are uncertain of the potential for harm of exercises, due to low event rates, and a limited number of studies reporting events. AUTHORS'
CONCLUSIONS: We found moderate- to low-quality evidence that exercise programmes probably slightly improve function, may reduce pain, and probably slightly reduce global patient assessment of disease activity, when compared with no intervention, and measured upon completion of the programme. We found moderate- to low-quality evidence that exercise programmes probably have little or no effect on improving function or reducing pain, when compared with usual care, and may have little or no effect on reducing patient assessment of disease activity, when measured upon completion of the programmes. We are uncertain whether exercise programmes improve spinal mobility, reduce fatigue, or induce adverse effects.

Entities:  

Year:  2019        PMID: 31578051      PMCID: PMC6774752          DOI: 10.1002/14651858.CD011321.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  79 in total

1.  Spondyloarthritis: may the force be with you?

Authors:  Dennis McGonagle; Rebecca C Thomas; Georg Schett
Journal:  Ann Rheum Dis       Date:  2013-11-12       Impact factor: 19.103

2.  The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis--a randomized controlled trial.

Authors:  G Kraag; B Stokes; J Groh; A Helewa; C Goldsmith
Journal:  J Rheumatol       Date:  1990-02       Impact factor: 4.666

Review 3.  Non-Radiographic Axial Spondyloarthritis.

Authors:  Gleb Slobodin; Iris Eshed
Journal:  Isr Med Assoc J       Date:  2015-12       Impact factor: 0.892

Review 4.  TNF-alpha inhibitors for ankylosing spondylitis.

Authors:  Lara J Maxwell; Jane Zochling; Annelies Boonen; Jasvinder A Singh; Mirella M S Veras; Elizabeth Tanjong Ghogomu; Maria Benkhalti Jandu; Peter Tugwell; George A Wells
Journal:  Cochrane Database Syst Rev       Date:  2015-04-18

5.  Gender-attributable differences in outcome of ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study.

Authors:  Casper Webers; Ivette Essers; Sofia Ramiro; Carmen Stolwijk; Robert Landewé; Désirée van der Heijde; Filip van den Bosch; Maxime Dougados; Astrid van Tubergen
Journal:  Rheumatology (Oxford)       Date:  2015-09-18       Impact factor: 7.580

Review 6.  Exercise therapy for spondyloarthritis: a systematic review.

Authors:  Tom O'Dwyer; Finbar O'Shea; Fiona Wilson
Journal:  Rheumatol Int       Date:  2014-02-19       Impact factor: 2.631

7.  The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis.

Authors:  Nigil Haroon; Robert D Inman; Thomas J Learch; Michael H Weisman; MinJae Lee; Mohammad H Rahbar; Michael M Ward; John D Reveille; Lianne S Gensler
Journal:  Arthritis Rheum       Date:  2013-10

8.  The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis.

Authors:  J Sieper; M Rudwaleit; X Baraliakos; J Brandt; J Braun; R Burgos-Vargas; M Dougados; K-G Hermann; R Landewé; W Maksymowych; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2009-06       Impact factor: 19.103

Review 9.  Exercise therapy for chronic low back pain.

Authors:  Jill A Hayden; Jenna Ellis; Rachel Ogilvie; Antti Malmivaara; Maurits W van Tulder
Journal:  Cochrane Database Syst Rev       Date:  2021-09-28

10.  Undue reliance on I(2) in assessing heterogeneity may mislead.

Authors:  Gerta Rücker; Guido Schwarzer; James R Carpenter; Martin Schumacher
Journal:  BMC Med Res Methodol       Date:  2008-11-27       Impact factor: 4.615

View more
  15 in total

1.  What are the potential benefits and harms of exercise programs for patients with ankylosing spondylitis? A Cochrane review summary with commentary.

Authors:  İlke Coşkun Benlidayı
Journal:  Turk J Phys Med Rehabil       Date:  2020-03-03

Review 2.  Treat-to-target in axial spondyloarthritis - what about physical function and activity?

Authors:  Jürgen Braun; Xenofon Baraliakos; Uta Kiltz
Journal:  Nat Rev Rheumatol       Date:  2021-07-26       Impact factor: 20.543

3.  Quality of internet videos related to exercise therapy of ankylosing spondylitis from mainland China : Content analysis.

Authors:  Yan Sang; Jialing Chen; Huiling Dai; Tiantian Chen; Bing Chen; Xia Li; Xiaohua Shen; Hailin Jiang
Journal:  Z Rheumatol       Date:  2020-12-01       Impact factor: 1.372

Review 4.  Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews.

Authors:  Rikke A Andreasen; Lars E Kristensen; Xenofon Baraliakos; Vibeke Strand; Philip J Mease; Maarten de Wit; Torkell Ellingsen; Inger Marie J Hansen; Jamie Kirkham; George A Wells; Peter Tugwell; Lara Maxwell; Maarten Boers; Kenneth Egstrup; Robin Christensen
Journal:  Arthritis Res Ther       Date:  2020-07-25       Impact factor: 5.156

5.  Australian Consensus Statements for the Assessment and Management of Non-radiographic Axial Spondyloarthritis.

Authors:  Steven L Truong; Tim McEwan; Paul Bird; Irwin Lim; Nivene F Saad; Lionel Schachna; Andrew L Taylor; Philip C Robinson
Journal:  Rheumatol Ther       Date:  2021-12-28

Review 6.  Wearable activity trackers and artificial intelligence in the management of rheumatic diseases : Where are we in 2021?

Authors:  Thomas Davergne; Joanna Kedra; Laure Gossec
Journal:  Z Rheumatol       Date:  2021-10-11       Impact factor: 1.372

7.  Tail suspension delays ectopic ossification in proteoglycan-induced ankylosing spondylitis in mice via miR-103/DKK1.

Authors:  Zhenzhen Zhang; Jing Zeng; Yang Li; Qing Liao; Dongdong Huang; Yucong Zou; Gang Liu
Journal:  Exp Ther Med       Date:  2021-07-07       Impact factor: 2.447

Review 8.  Wearable Activity Trackers in the Management of Rheumatic Diseases: Where Are We in 2020?

Authors:  Thomas Davergne; Antsa Rakotozafiarison; Hervé Servy; Laure Gossec
Journal:  Sensors (Basel)       Date:  2020-08-25       Impact factor: 3.576

Review 9.  Effectiveness of Physiotherapy in Patients with Ankylosing Spondylitis: A Systematic Review and Meta-Analysis.

Authors:  Luca Pontone Gravaldi; Francesca Bonetti; Simona Lezzerini; Fernando De Maio
Journal:  Healthcare (Basel)       Date:  2022-01-10

10.  Effectiveness and safety of Chinese herbal formula combined with western medicine for ankylosing spondylitis: A protocol for systematic review and meta-analysis.

Authors:  Miao Liu; Xiao-Lei Deng; Jing Yu
Journal:  Medicine (Baltimore)       Date:  2021-06-25       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.